Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CYLD drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CYLD Wild-Type & Catalytic Inactive Mutant (C601S) Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CYLD Products |
| Gene Delivery | CYLD Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CYLD Products |
| Benchmark Ab | Anti-CYLD Recombinant Antibody Recombinant positive control for Western Blot and Flow Cytometry. |
View CYLD Products |
| Validator | CYLD siRNA Set For knockdown verification in functional assays. |
View CYLD Products |
| Related Target A | TRAF2 Direct substrate of CYLD; key node in NF-kB activation and necroptosis pathways. |
View TRAF2 Products |
| Related Target B | RIPK1 Regulated by CYLD deubiquitination; crucial mediator of necroptosis and cell survival. |
View RIPK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Differentiating target-specific DUB activity from background deubiquitinase noise | Catalytic inactive mutant (C601S) available as a strict negative control to validate enzymatic assay specificity. |
| Achieving high-level, stable intracellular expression for phenotypic screening | High-titer Lentivirus premade particles designed for stable cell line construction to preserve native conformation and complexes. |
| Lack of reliable positive control reagents | Sequence-verified positive control antibodies and target-specific validated siRNA sets included. |
| Ensuring structural integrity of intracellular DUB proteins | E. coli or eukaryotic expression systems optimized for solubility, with purity checked by SDS-PAGE (>95%). |
Live CYLD R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development surrounding CYLD (Cylindromatosis lysine-specific deubiquitinase) is highly focused on its role as a key tumor suppressor and negative regulator of the NF-kB, Wnt, and necroptosis signaling pathways. The loss or downregulation of CYLD is implicated in multiple cancers (such as cylindromatosis, T-cell acute lymphoblastic leukemia, and hepatocellular carcinoma) as well as chronic inflammatory diseases.
The race for CYLD therapeutics is intensifying, with major players shifting focus from traditional gene replacement therapies to small molecule modulators, PROTACs targeting regulatory proteins, and combination strategies with immune checkpoint inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting the precise restoration of CYLD activity or utilizing CYLD expression status as a biomarker for synthetic lethality screens.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / mRNA | Academic Institutes, Biotech Startups | Cylindromatosis, Monogenic Disorders | Expression validation (Need high-titer Lentivirus and validated siRNA) |
| Small Molecule Enhancers | Pharmaceutical Innovators | Inflammatory Diseases, Solid Tumors | Enzymatic activity assays (Need WT vs Mutant C601S proteins) |
| Synthetic Lethality / DUB Inhibitors | Oncology-focused Biotechs | CYLD-deficient Cancers | Off-target screening (Need USP/DUB family homolog panel) |